BioSenic S.A. (BIOS.BR)
EUR 0.0
(-12.9%)
EUR 0.0
(-12.9%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 543 Thousand EUR | 50.0% |
| 2022 | 206 Thousand EUR | -79.13% |
| 2021 | 987 Thousand EUR | -1.3% |
| 2020 | 1 Million EUR | 538.6% |
| 2019 | -228 Thousand EUR | -122.8% |
| 2018 | 1 Million EUR | 307.9% |
| 2017 | -481 Thousand EUR | 9.93% |
| 2016 | -534 Thousand EUR | -36.22% |
| 2015 | -392 Thousand EUR | 0.0% |
| 2014 | - EUR | 0.0% |
| 2013 | - EUR | 0.0% |
| 2012 | - EUR | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | 1.24 Million EUR | 0.0% |
| 2024 Q1 | 1.34 Million EUR | 3161.36% |
| 2023 FY | 309 Thousand EUR | 50.0% |
| 2023 Q1 | 182.5 Thousand EUR | 158.87% |
| 2023 Q2 | 81.5 Thousand EUR | -55.34% |
| 2023 Q3 | 89 Thousand EUR | 9.2% |
| 2023 Q4 | -44 Thousand EUR | -149.44% |
| 2022 Q4 | 70.5 Thousand EUR | 0.0% |
| 2022 FY | 206 Thousand EUR | -79.13% |
| 2022 Q3 | 70.5 Thousand EUR | 161.84% |
| 2022 Q2 | -114 Thousand EUR | 0.0% |
| 2021 Q4 | 930 Thousand EUR | 0.0% |
| 2021 FY | 987 Thousand EUR | -1.3% |
| 2021 Q2 | -64 Thousand EUR | 0.0% |
| 2020 Q4 | 1 Million EUR | 0.0% |
| 2020 FY | 1 Million EUR | 538.6% |
| 2020 Q2 | -351 Thousand EUR | 0.0% |
| 2019 FY | -228 Thousand EUR | -122.8% |
| 2019 Q2 | -389 Thousand EUR | 0.0% |
| 2019 Q4 | -363 Thousand EUR | 0.0% |
| 2018 Q4 | 1 Million EUR | 0.0% |
| 2018 FY | 1 Million EUR | 307.9% |
| 2017 FY | -481 Thousand EUR | 9.93% |
| 2016 FY | -534 Thousand EUR | -36.22% |
| 2015 FY | -392 Thousand EUR | 0.0% |
| 2014 Q3 | - EUR | 0.0% |
| 2014 FY | - EUR | 0.0% |
| 2014 Q4 | - EUR | 0.0% |
| 2013 Q4 | - EUR | 0.0% |
| 2013 FY | - EUR | 0.0% |
| 2012 FY | - EUR | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| ABIONYX Pharma SA | 618 Thousand EUR | 12.136% |
| ABIVAX Société Anonyme | 3.91 Million EUR | 86.127% |
| Adocia SA | 1.38 Million EUR | 60.794% |
| Aelis Farma SA | 12.35 Million EUR | 95.606% |
| Biophytis S.A. | -803 Thousand EUR | 167.621% |
| Advicenne S.A. | 1.42 Million EUR | 61.921% |
| genOway Société anonyme | 20.1 Million EUR | 97.299% |
| IntegraGen SA | 5.01 Million EUR | 89.18% |
| Medesis Pharma S.A. | -2.66 Million EUR | 120.377% |
| Neovacs S.A. | 29.31 Thousand EUR | -1752.357% |
| NFL Biosciences SA | -56.06 Thousand EUR | 1068.536% |
| Plant Advanced Technologies SA | 2.15 Million EUR | 74.778% |
| Quantum Genomics Société Anonyme | -1.41 Million EUR | 138.259% |
| Sensorion SA | 3.78 Million EUR | 85.665% |
| Theranexus Société Anonyme | -4.63 Million EUR | 111.706% |
| TME Pharma N.V. | -127 Thousand EUR | 527.559% |
| Valbiotis SA | 2.66 Million EUR | 79.648% |
| TheraVet SA | -530.79 Thousand EUR | 202.299% |
| Valerio Therapeutics Société anonyme | 1.26 Million EUR | 57.143% |
| argenx SE | 925.49 Million EUR | 99.941% |
| Celyad Oncology SA | 33 Thousand EUR | -1545.455% |
| DBV Technologies S.A. | 4.15 Million EUR | 86.946% |
| Galapagos NV | 203.73 Million EUR | 99.733% |
| Genfit S.A. | 28.22 Million EUR | 98.076% |
| GeNeuro SA | -293.8 Thousand EUR | 284.82% |
| Hyloris Pharmaceuticals SA | 1.99 Million EUR | 72.768% |
| Innate Pharma S.A. | -4.12 Million EUR | 113.176% |
| Inventiva S.A. | 17.5 Million EUR | 96.897% |
| MaaT Pharma SA | 1.65 Million EUR | 67.19% |
| MedinCell S.A. | 9.28 Million EUR | 94.154% |
| Nanobiotix S.A. | 36.2 Million EUR | 98.5% |
| Onward Medical N.V. | -14.81 Million EUR | 103.664% |
| Oryzon Genomics S.A. | 13.94 Million EUR | 96.107% |
| OSE Immunotherapeutics SA | 2.22 Million EUR | 75.617% |
| Oxurion NV | 104 Thousand EUR | -422.115% |
| Pharming Group N.V. | 220.1 Million EUR | 99.753% |
| Poxel S.A. | 1000.00 EUR | -54200.0% |
| GenSight Biologics S.A. | 3 Million EUR | 81.9% |
| Transgene SA | -28.4 Million EUR | 101.912% |
| Financière de Tubize SA | -2.02 Million EUR | 126.754% |
| UCB SA | 3.34 Billion EUR | 99.984% |
| Valneva SE | 52.83 Million EUR | 98.972% |
| Vivoryon Therapeutics N.V. | -3.09 Million EUR | 117.544% |